Cargando…

Improving Cognitive Function Through High-Intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy: Protocol for a Randomized Controlled Trial

BACKGROUND: More than 75% of patients with breast cancer treated with chemotherapy experience cognitive impairments (eg, memory and attention problems), commonly known as chemo-brain. Exercise, especially aerobic high-intensity interval training (HIIT), is associated with better cognitive function i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Rebekah, Kang, Dong-Woo, Tahbaz, Meghan, Norris, Mary, Uno, Hajime, Ligibel, Jennifer, Guenette, Jeffrey, Christopher, Cameron, Dieli-Conwright, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132015/
https://www.ncbi.nlm.nih.gov/pubmed/37027186
http://dx.doi.org/10.2196/39740
_version_ 1785031307794841600
author Wilson, Rebekah
Kang, Dong-Woo
Tahbaz, Meghan
Norris, Mary
Uno, Hajime
Ligibel, Jennifer
Guenette, Jeffrey
Christopher, Cameron
Dieli-Conwright, Christina
author_facet Wilson, Rebekah
Kang, Dong-Woo
Tahbaz, Meghan
Norris, Mary
Uno, Hajime
Ligibel, Jennifer
Guenette, Jeffrey
Christopher, Cameron
Dieli-Conwright, Christina
author_sort Wilson, Rebekah
collection PubMed
description BACKGROUND: More than 75% of patients with breast cancer treated with chemotherapy experience cognitive impairments (eg, memory and attention problems), commonly known as chemo-brain. Exercise, especially aerobic high-intensity interval training (HIIT), is associated with better cognitive function in healthy populations. However, clinical trials testing the impact of exercise interventions on chemotherapy-induced cognitive decline in patients with cancer are lacking, and the mechanisms through which exercise could improve cognitive function are unclear. OBJECTIVE: The objective of the Improving Cognitive Function Through High-Intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy trial is to examine the effects of HIIT on cognitive function in patients with breast cancer undergoing chemotherapy. METHODS: This 2-arm, single-center, pilot randomized controlled trial will randomize 50 patients with breast cancer undergoing chemotherapy to HIIT or attention control. The HIIT group will perform a supervised 16-week, thrice-weekly intervention, with each session including a 5-minute warm-up at 10% maximal power output (POmax), 10 sets of alternating 1-minute high-intensity (90% POmax) and 1-minute recovery (10% POmax) intervals, and a 5-minute cooldown (10% POmax). The attention control group will receive a stretching program with no exercise components and be asked to maintain their exercise levels for 16 weeks. The primary outcomes of the study are executive function and memory measured using the National Institutes of Health toolbox and resting-state connectivity and diffusion tensor imaging microstructure evaluated using magnetic resonance imaging. The secondary and tertiary outcomes include cardiorespiratory fitness, body composition, physical fitness, and psychosocial health. The study has been approved by the institutional review board of the Dana-Farber Cancer Institute (20-222). RESULTS: The trial was funded in January 2019, with recruitment started in June 2021. As of May 2022, a total of 4 patients have consented and been randomized (n=2, 50% to exercise; n=1, 25% to control; and n=1, 25% nonrandomized). Trial completion is expected in January 2024. CONCLUSIONS: This first-of-its-kind study incorporates a novel exercise intervention (ie, HIIT) and comprehensive cognitive measures. If positive, our findings will establish the pilot efficacy of HIIT on chemotherapy-induced cognitive function in patients with breast cancer, providing the foundation for future larger phase-II and phase-III trials to confirm the findings and potentially establish HIIT as a standard of care for women undergoing chemotherapy for breast cancer. TRIAL REGISTRATION: ClinicalTrials.gov NCT04724499; https://clinicaltrials.gov/ct2/show/NCT04724499 INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/39740
format Online
Article
Text
id pubmed-10132015
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-101320152023-04-27 Improving Cognitive Function Through High-Intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy: Protocol for a Randomized Controlled Trial Wilson, Rebekah Kang, Dong-Woo Tahbaz, Meghan Norris, Mary Uno, Hajime Ligibel, Jennifer Guenette, Jeffrey Christopher, Cameron Dieli-Conwright, Christina JMIR Res Protoc Protocol BACKGROUND: More than 75% of patients with breast cancer treated with chemotherapy experience cognitive impairments (eg, memory and attention problems), commonly known as chemo-brain. Exercise, especially aerobic high-intensity interval training (HIIT), is associated with better cognitive function in healthy populations. However, clinical trials testing the impact of exercise interventions on chemotherapy-induced cognitive decline in patients with cancer are lacking, and the mechanisms through which exercise could improve cognitive function are unclear. OBJECTIVE: The objective of the Improving Cognitive Function Through High-Intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy trial is to examine the effects of HIIT on cognitive function in patients with breast cancer undergoing chemotherapy. METHODS: This 2-arm, single-center, pilot randomized controlled trial will randomize 50 patients with breast cancer undergoing chemotherapy to HIIT or attention control. The HIIT group will perform a supervised 16-week, thrice-weekly intervention, with each session including a 5-minute warm-up at 10% maximal power output (POmax), 10 sets of alternating 1-minute high-intensity (90% POmax) and 1-minute recovery (10% POmax) intervals, and a 5-minute cooldown (10% POmax). The attention control group will receive a stretching program with no exercise components and be asked to maintain their exercise levels for 16 weeks. The primary outcomes of the study are executive function and memory measured using the National Institutes of Health toolbox and resting-state connectivity and diffusion tensor imaging microstructure evaluated using magnetic resonance imaging. The secondary and tertiary outcomes include cardiorespiratory fitness, body composition, physical fitness, and psychosocial health. The study has been approved by the institutional review board of the Dana-Farber Cancer Institute (20-222). RESULTS: The trial was funded in January 2019, with recruitment started in June 2021. As of May 2022, a total of 4 patients have consented and been randomized (n=2, 50% to exercise; n=1, 25% to control; and n=1, 25% nonrandomized). Trial completion is expected in January 2024. CONCLUSIONS: This first-of-its-kind study incorporates a novel exercise intervention (ie, HIIT) and comprehensive cognitive measures. If positive, our findings will establish the pilot efficacy of HIIT on chemotherapy-induced cognitive function in patients with breast cancer, providing the foundation for future larger phase-II and phase-III trials to confirm the findings and potentially establish HIIT as a standard of care for women undergoing chemotherapy for breast cancer. TRIAL REGISTRATION: ClinicalTrials.gov NCT04724499; https://clinicaltrials.gov/ct2/show/NCT04724499 INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/39740 JMIR Publications 2023-04-07 /pmc/articles/PMC10132015/ /pubmed/37027186 http://dx.doi.org/10.2196/39740 Text en ©Rebekah Wilson, Dong-Woo Kang, Meghan Tahbaz, Mary Norris, Hajime Uno, Jennifer Ligibel, Jeffrey Guenette, Cameron Christopher, Christina Dieli-Conwright. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 07.04.2023. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on https://www.researchprotocols.org, as well as this copyright and license information must be included.
spellingShingle Protocol
Wilson, Rebekah
Kang, Dong-Woo
Tahbaz, Meghan
Norris, Mary
Uno, Hajime
Ligibel, Jennifer
Guenette, Jeffrey
Christopher, Cameron
Dieli-Conwright, Christina
Improving Cognitive Function Through High-Intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy: Protocol for a Randomized Controlled Trial
title Improving Cognitive Function Through High-Intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy: Protocol for a Randomized Controlled Trial
title_full Improving Cognitive Function Through High-Intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy: Protocol for a Randomized Controlled Trial
title_fullStr Improving Cognitive Function Through High-Intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy: Protocol for a Randomized Controlled Trial
title_full_unstemmed Improving Cognitive Function Through High-Intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy: Protocol for a Randomized Controlled Trial
title_short Improving Cognitive Function Through High-Intensity Interval Training in Breast Cancer Patients Undergoing Chemotherapy: Protocol for a Randomized Controlled Trial
title_sort improving cognitive function through high-intensity interval training in breast cancer patients undergoing chemotherapy: protocol for a randomized controlled trial
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132015/
https://www.ncbi.nlm.nih.gov/pubmed/37027186
http://dx.doi.org/10.2196/39740
work_keys_str_mv AT wilsonrebekah improvingcognitivefunctionthroughhighintensityintervaltraininginbreastcancerpatientsundergoingchemotherapyprotocolforarandomizedcontrolledtrial
AT kangdongwoo improvingcognitivefunctionthroughhighintensityintervaltraininginbreastcancerpatientsundergoingchemotherapyprotocolforarandomizedcontrolledtrial
AT tahbazmeghan improvingcognitivefunctionthroughhighintensityintervaltraininginbreastcancerpatientsundergoingchemotherapyprotocolforarandomizedcontrolledtrial
AT norrismary improvingcognitivefunctionthroughhighintensityintervaltraininginbreastcancerpatientsundergoingchemotherapyprotocolforarandomizedcontrolledtrial
AT unohajime improvingcognitivefunctionthroughhighintensityintervaltraininginbreastcancerpatientsundergoingchemotherapyprotocolforarandomizedcontrolledtrial
AT ligibeljennifer improvingcognitivefunctionthroughhighintensityintervaltraininginbreastcancerpatientsundergoingchemotherapyprotocolforarandomizedcontrolledtrial
AT guenettejeffrey improvingcognitivefunctionthroughhighintensityintervaltraininginbreastcancerpatientsundergoingchemotherapyprotocolforarandomizedcontrolledtrial
AT christophercameron improvingcognitivefunctionthroughhighintensityintervaltraininginbreastcancerpatientsundergoingchemotherapyprotocolforarandomizedcontrolledtrial
AT dieliconwrightchristina improvingcognitivefunctionthroughhighintensityintervaltraininginbreastcancerpatientsundergoingchemotherapyprotocolforarandomizedcontrolledtrial